[{"id":"6ae91b16-28e3-42da-b2eb-0dd1d16d9e97","acronym":"","url":"https://clinicaltrials.gov/study/NCT05826015","created_at":"2023-04-24T14:03:55.315Z","updated_at":"2024-07-02T16:34:26.698Z","phase":"Phase 1","brief_title":"AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","source_id_and_acronym":"NCT05826015","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["HER-2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • batiraxcept (AVB-500)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 06/03/2029","primary_completion_date":" 06/03/2029","study_txt":" Completion: 06/04/2034","study_completion_date":" 06/04/2034","last_update_posted":"2024-06-12"},{"id":"4d0513e0-80e4-4c43-823b-9318af895a28","acronym":"AVB500-OC-002","url":"https://clinicaltrials.gov/study/NCT03639246","created_at":"2021-01-18T17:52:08.158Z","updated_at":"2024-07-02T16:35:55.705Z","phase":"Phase 1b/2","brief_title":"Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03639246 - AVB500-OC-002","lead_sponsor":"Aravive, Inc.","biomarkers":" GAS6","pipe":"","alterations":" ","tags":["GAS6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • batiraxcept (AVB-500) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/06/2018","start_date":" 12/06/2018","primary_txt":" Primary completion: 01/08/2021","primary_completion_date":" 01/08/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2023-02-13"}]